TY - JOUR
T1 - The Role of Tissue Factor in Atherothrombosis and Coronary Artery Disease
T2 - Insights into Platelet Tissue Factor
AU - Camera, Marina
AU - Toschi, Vincenzo
AU - Brambilla, Marta
AU - Lettino, Maddalena
AU - Rossetti, Laura
AU - Canzano, Paola
AU - Di Minno, Alessandro
AU - Tremoli, Elena
PY - 2015/9/26
Y1 - 2015/9/26
N2 - The contribution of vessel wall-derived tissue factor (TF) to atherothrombosis is well established, whereas the pathophysiological relevance of the blood-borne TF is still a matter of debate, and controversies on the presence of platelet-associated TF still exist. In the past 15 years, several studies have documented the presence of TF in human platelets, the capacity of human platelets to use TF mRNA to make de novo protein synthesis, and the increase in the percentage of TF positive platelets in pathological conditions such as coronary artery disease (CAD). The exposure of vessel wall-derived TF at the site of vascular injury would play its main role in the initiation phase, whereas the blood-borne TF carried by platelets would be involved in the propagation phase of thrombus formation. More recent data indicate that megakaryocytes are committed to release into the bloodstream a well-defined number of TF-carrying platelets, which represents only a fraction of the whole platelet population. These findings are in line with the evidence that platelets are heterogeneous in their functions and only a subset of them is involved in the hemostatic process. In this review we summarize the existing knowledge on platelet associated TF and speculate on its relevance to physiology and to atherothrombosis and CAD.
AB - The contribution of vessel wall-derived tissue factor (TF) to atherothrombosis is well established, whereas the pathophysiological relevance of the blood-borne TF is still a matter of debate, and controversies on the presence of platelet-associated TF still exist. In the past 15 years, several studies have documented the presence of TF in human platelets, the capacity of human platelets to use TF mRNA to make de novo protein synthesis, and the increase in the percentage of TF positive platelets in pathological conditions such as coronary artery disease (CAD). The exposure of vessel wall-derived TF at the site of vascular injury would play its main role in the initiation phase, whereas the blood-borne TF carried by platelets would be involved in the propagation phase of thrombus formation. More recent data indicate that megakaryocytes are committed to release into the bloodstream a well-defined number of TF-carrying platelets, which represents only a fraction of the whole platelet population. These findings are in line with the evidence that platelets are heterogeneous in their functions and only a subset of them is involved in the hemostatic process. In this review we summarize the existing knowledge on platelet associated TF and speculate on its relevance to physiology and to atherothrombosis and CAD.
KW - atherothrombosis
KW - coronary artery disease
KW - megakaryocytes
KW - platelets
KW - tissue factor
UR - http://www.scopus.com/inward/record.url?scp=84943609767&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84943609767&partnerID=8YFLogxK
U2 - 10.1055/s-0035-1564041
DO - 10.1055/s-0035-1564041
M3 - Article
C2 - 26408918
AN - SCOPUS:84943609767
VL - 41
SP - 737
EP - 746
JO - Seminars in Thrombosis and Hemostasis
JF - Seminars in Thrombosis and Hemostasis
SN - 0094-6176
IS - 7
ER -